Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, oncology, and other areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE, glatiramer acetate injection to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of tardive dyskinesia, chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder; and ProAir RespiClick inhalation powder. It offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. The company has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. Teva Pharmaceutical Industries Limited was founded in 1901 and is based in Tel Aviv-Yafo, Israel.…
Celldex drug stumbles in eczema; Epigenetic editing startup cuts staff
Teva Pharmaceutical Industries Targets Up to $7 Billion in Innovative Drug Revenue by 2030
Teva Pharmaceutical Industries (NYSE: TEVA) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 31,173 employees.
The shares were at 39.23 USD on 20 November 2026, up 60.5% over 52 weeks. Its 52-week range is 24.01 USD to 44.56 USD: the price is 12.0% below the high and 63.4% above the low.
At a market capitalisation of 45.77B USD, it trades at 91.2 times trailing earnings and 12.5 times forward earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 24.5, a premium of 272% for TEVA.
Teva Pharmaceutical Industries reports return on equity of 17.8%, an operating margin of 19.8% and revenue down 1.9% year over year.
Its debt exceeds its cash by 12.91B USD, a debt-to-equity ratio of 2.16. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 14 analysts cover the stock, with an average rating of Buy; their mean price target of 50.51 USD is 28.7% above the current price. The next earnings report is expected on 27 January 2027.